Clinical Trials Logo

Immune Thrombocytopenia Purpura clinical trials

View clinical trials related to Immune Thrombocytopenia Purpura.

Filter by:
  • None
  • Page 1

NCT ID: NCT06288932 Recruiting - Clinical trials for Immune Thrombocytopenia Purpura

Outcome Study of Conventional Steroids vs. Steroids Combined With Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.

Start date: February 2024
Phase: Phase 3
Study type: Interventional

Immune thrombocytopenia Purpura (ITP) is an autoimmune condition delineated by humoral as well as cell mediated immune response against thrombocyte surface proteins GPIIb/IIIa receptors, affecting primary homeostasis leading to mucocutaneous bleeding.ITP is characterized by platelet count <100 x 109/L. The conventional line of treatment for newly diagnosed ITP is steroids but significant disadvantages have been associated with long term use and a high risk of relapse when reducing the dose. The addition of MMF to the first line treatment of ITP resulted in substantial response and a lower risk of refractory ITP with decreased financial burden and improved outcome.

NCT ID: NCT05861297 Recruiting - Clinical trials for Immune Thrombocytopenia Purpura

Immune Thrombocytopenia Management in Adults

Start date: May 5, 2020
Phase: Phase 4
Study type: Interventional

Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only benefits without drawbacks. This study compares the clinical outcomes and adverse drug patterns of different treatment options. Medications which will be assessed during the current study are High Dose-dexamethasone (HD-DXM) (control group), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim.

NCT ID: NCT01963260 Completed - Clinical trials for Immune Thrombocytopenia Purpura

Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

Start date: October 31, 2013
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to assess the safety and tolerability of single rising doses of MK-8723 in healthy adult participants and adult participants with chronic immune thrombocytopenia purpura (ITP) and to assess pharmacodynamics of MK-8723 in participants with ITP. The primary hypothesis is that the true placebo-adjusted platelet response rate to MK-8723 in adult patients with chronic ITP is >50%.